Kalaris Therapeutics Inc

KLRS | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.22

-$0.02 (-0.77%)

Sep 22, 2026, 2:31 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.77%

(1D)

Rating

Updated: Sep 12, 2026

19.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $70.28M

1D Range

3.16 3.29

52W Range

3.03 11.88

Valuation (TTM)

PE -1.61

PB 1.23

EV/EBITDA 1.62

Valuation (NTM)

Forward PE N/A

Forward PEG 0.09

Price Target $15.50

Cash Flow

FCF Yield -64.4%

SBC Adj. FCF Yield -65.3%

SBC Impact -1.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 50.7% | 58.3%

FCF 3Y | 5Y 25.9% | 34.3%

Returns

ROA -44.5%

ROE -71.7%

ROIC -52.4%

Financial Health

Net Cash

$143.56M

Current Ratio 10.98

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-sta...

Sector Healthcare

Industry Biotechnology

Employees 20

IPO Date Jul 29, 2020

Website kalaristx.com

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$15.50

Upside

+381.37%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞